Multicenter Prospective Cohort of Sepsis and ARDS in China
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China23 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 6,000 people, planned
- Started
- 1 May 2022
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Surveys
- 6-Minute Walk Test
- Blood collection
- Pulmonary & Respiratory Muscle Function Testing
- CT Scan
- Bronchoalveolar Lavage Fluid
- HME filter samples
- Record updated
- 7 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥18 years
- Meets the diagnostic criteria for sepsis and/or acute respiratory distress syndrome (ARDS):; Sepsis: Sepsis is defined according to the Sepsis-3 criteria as suspected or confirmed infection accompanied by acute organ dysfunction attributable to infection, operationalized as an increase in the Sequential Organ Failure Assessment (SOFA) score of ≥2 points from baseline; ARDS: ARDS is diagnosed according to the 2024 Global Definition of ARDS, including an acute predisposing condition or risk factor, acute onset or worsening of respiratory symptoms, bilateral pulmonary opacities on chest imaging or lung ultrasound not fully explained by pleural effusion, atelectasis, or pulmonary nodules, hypoxemia meeting the corresponding oxygenation criteria, and pulmonary edema not primarily attributable to cardiogenic causes or fluid overload
- Admitted to an ICU or other designated inpatient unit at a participating study center, including emergency or respiratory care units where appropriate
- Written informed consent is obtained from the participant or a legally authorized representative, or deferred consent is used when permitted by local ethical requirements
Who cannot take part
- Previous enrollment in this cohort. Each participant may be enrolled only once; subsequent episodes of sepsis and/or ARDS may be recorded as clinical events but will not result in repeated enrollment
- Participant withdrawal: Participants or their legally authorized representatives may withdraw consent at any time. No new study-specific data will be collected after withdrawal. The use of previously collected data and stored biological samples will follow the participant's consent and applicable ethical requirements
- The acute clinical condition is primarily explained by an alternative diagnosis without sepsis or ARDS, such as isolated cardiogenic pulmonary edema or fluid overload without ARDS
- Terminal illness with an expected survival of <24 hours, or a decision for comfort measures only has been made before enrollment
- Any other condition that, in the investigator's judgment, makes participation inappropriate; Withdrawal and Loss to Follow-up:
- Investigator-initiated withdrawal: Participants may be withdrawn if subsequent review identifies a major protocol violation, duplicate enrollment, unreliable study data, or another condition that makes continued participation inappropriate
- Informed consent cannot be obtained in accordance with applicable ethical requirements
- Loss to follow-up: Participants who cannot be contacted after repeated attempts and for whom follow-up information cannot be obtained through other permitted sources will be considered lost to follow-up. Data collected before loss to follow-up may be retained and analyzed according to the statistical analysis plan
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, multicenter, observational cohort study enrolls 6,000 adults with sepsis and/or acute respiratory distress syndrome (ARDS) at multiple hospitals in China. Clinical data, treatment information, biological samples, and follow-up data are collected to characterize patient features and outcomes and to establish a multicenter clinical cohort and biobank.
Read full original descriptionShow less
The study focuses on the clinical and biological heterogeneity of sepsis and ARDS. Longitudinal clinical data are integrated with information on organ function, inflammatory and immune responses, and multi-omics profiles to identify clinically relevant phenotypes and biological subgroups. Biomarkers associated with disease severity, organ dysfunction, treatment response, and mortality are explored, together with models for outcome prediction. Follow-up after hospitalization evaluates long-term survival and recovery, including pulmonary function, physical function, quality of life, and psychological health.
The 2 groups in the trial
- Hospitalized Cohort
Patients with Sepsis/ARDS enrolled during hospitalization will undergo prospective collection of clinical data and biospecimens during the acute phase of illness. Clinical characteristics, treatments, organ support, and in-hospital outcomes will also be recorded.
Treatment: Blood Collection, Bronchoalveolar Lavage Fluid, and HME filter samples
- Long-term Follow-up Cohort
Participants enrolled in the hospitalized Sepsis/ARDS cohort who survive and are available for follow-up will undergo longitudinal assessments at 1, 6, 12, and 24 months following hospital discharge, including evaluation of quality of life, physical function, pulmonary function, imaging, and biospecimen collection.
Treatment: Surveys, 6-Minute Walk Test, Blood collection, Pulmonary & Respiratory Muscle Function Testing, and CT Scan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sepsis and Acute Respiratory Distress Syndrome in China (SEARCH): A Multicenter Prospective Observational Study of Clinical and Biological Phenotypes
- Record updated
- 7 October 2026